| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.10. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| ABVC BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 27.06. | ABVC BIOPHARMA, INC. - S-8, Securities to be offered to employees in employee benefit plans | 15 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,500 | -2,91 % | NanoRepro: Zwei Aufsichtsräte treten zurück | Nachdem NanoRepro am Freitag das Verlangen der HWT invest Aktiengesellschaft auf Einberufung einer außerordentlichen Hauptversammlung publik gemacht hat, sind nun zwei Aufsichtsräte zurückgetreten.... ► Artikel lesen | |
| BIOXXMED | 0,023 | 0,00 % | HV-Termine: Hauptversammlungen bei bioXXmed, Borussia Dortmund, CureVac, elexxion, Nanofocus, NSI Asset, OTRS | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,190 | 0,00 % | RedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells | Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as... ► Artikel lesen | |
| CELLECTIS | 3,755 | +6,52 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis | Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and... ► Artikel lesen | |
| ALTERITY THERAPEUTICS | 0,004 | 0,00 % | XFRA PBN: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| SERES THERAPEUTICS | 13,620 | +4,29 % | Seres Therapeutics, Inc.: Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 | CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 0,108 | -1,82 % | Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space | Windtree is executing its corporate strategy to diversify its business with revenue and profit generating divisions CommLoan, Inc. is a tech company focused on transforming the way middle market loans... ► Artikel lesen | |
| ALTAMIRA THERAPEUTICS | 0,300 | 0,00 % | Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Certification of Bentrio Nasal Spray under Medical Device Regulation | Conformity with stringent new EU regulations for medical devices confirmedAllows for commercialization of Bentrio in EU member states; facilitates regulatory approval in various other countriesMajor... ► Artikel lesen | |
| MONOPAR THERAPEUTICS | 56,50 | 0,00 % | Monopar Therapeutics Inc.: Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments | WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| CLEARMIND MEDICINE | 2,256 | 0,00 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenGB00BR3SVZ18 Meridian Mining PLC 12.12.2025 GB00BVPND783 Meridian Mining PLC 15.12.2025 Tausch 1:1US75973T1016 Renalytix... ► Artikel lesen | |
| SCISPARC | 1,540 | 0,00 % | SciSparc Ltd: SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company | TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage... ► Artikel lesen | |
| ADITXT | 1,260 | 0,00 % | Why Aditxt Shares Are Trading Higher By Around 63%; Here Are 20 Stocks Moving Premarket | ||
| ENSYSCE BIOSCIENCES | 1,140 | 0,00 % | Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid | ~ Engineered to Deliver Potent Pain Relief with Unique, Built-In, Abuse Protection ~ SAN DIEGO, CA / ACCESS Newswire / December 9, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company")... ► Artikel lesen | |
| BIOCARDIA | 1,295 | +1,97 % | BioCardia, Inc. - S-8, Securities to be offered to employees in employee benefit plans |